Discover & Learn

Come and see it first.
 

Built by the team behind NEPTIS^® with 20 years of radiochemistry expertise, something new is about to be revealed this autumn. Discover the latest IBA radiochemistry technology!
 

October 18 – 2.45 pm

Louvain-la-Neuve, Belgium, October 15^th, 7 a.m. - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, today announced that a leading global producer and distributor of radiopharmaceuticals has selected IBA as preferred vendor for the expansion of its production network in the United States with an order of 12 Cyclone^® KIUBE 300 solutions to secure the production of radioisotopes for diagnostic and therapeutic applications.

Industrial capacity has become the gating factor in radiopharmaceuticals today. Clinical pipelines are broadening across both diagnostics and therapy, while supply, licensing and production capacity set the pace at which they reach patients. The new collaboration between this leading global producer and IBA answers that need directly: production capacity secured at network scale in the largest radiopharmaceutical market, with every system configured for fluorine-18 (¹⁸F) volume today and for radiometals as the therapeutic pipeline matures. The collaboration represents a capacity commitment made ahead of demand rather than in reaction to it.

This contract covers an order for 12 Cyclone^® KIUBE 300 systems, each equipped with multiple Nirta^® HCFT ¹⁸F helium cooling free targets as well as service like IntegraLab^® facility design, installation and commissioning, KARE Portal access, and operator and maintenance training. The systems will be deployed as a national production network across multiple sites in the United States, intended for high-volume commercial PET tracer production with ¹⁸F at the core.

Loïk-Maël Nys, President of IBA RadioPharma Solutions, commented: “We are pleased to have been selected by one of the world’s key players in the production of radiopharmaceuticals to support their expansion plan in the United States. Deploying 12 high-output cyclotrons across a national network within a short timeframe is a significant undertaking, reflecting IBA's unique ability to manufacture at scale, execute consistently and integrate the services required to design, install, commission and support production facilities over time. This collaboration also reflects our commitment to providing solutions that bring better outcomes to patients. We look forward to continuing to work together and help expand access to life-changing diagnostic and therapeutic radiopharmaceuticals, in the US and beyond.”

IBA's advanced technologies expertise
IBA is a leading supplier of PET and SPECT cyclotrons, with more than 350 systems installed worldwide. It is the only supplier able to cover the full 9 to 70 MeV range, with upgrades available on a CAPEX-only basis over 20 years. Each IBA system is supported with two decades of servicing, spare-parts supply and upgrade activities. Its advanced technology is backed on the ground by an efficient locally integrated service organisation with more than 40 years in the market, dedicated field engineers and a dedicated area spare parts hub. 

The Cyclone^® KIUBE platform delivers on both performance and reliability: the system can produce up to 35 Ci of ¹⁸F in a single two-hour dual beam run, driving +42% FDG revenue and +76% FDG EBIT per site compared with the leading competing platform. Fleet uptime remains above 97%, thanks to redundancy built into every main subsystem.

IBA organizes biennial users meetings involving all PET cyclotrons and chemistry customers all around the world. Our experience shows that gathering people together encourages creativity and helps IBA to develop priorities jointly with customers.

For this edition, we were welcome by CHU Quebec.

Every morning, in every radiopharmacy, it’s the same ritual. It works and worked for years, but you know what it costs you, day after day.
 

This autumn, something is changing. Built by the team behind NEPTIS^® with 20 years of radiochemistry expertise, something new is about to be revealed.
 

When will it be revealed?

• Sunday, October 18, 2.45 PM
• IBA booth #413
   

Seats are limited → book your seat now

Louvain-la-Neuve, Belgium, October 1^st, 7 a.m. - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions today announced a new agreement with ARTMS Inc. (a Telix company) for IBA to distribute ARTMS’s proprietary solid-target cyclotron technology, known as QUANTM^® Irradiation System (QIS^®), to support the expansion of theranostics worldwide.

With QIS^® referenced in FDA filings for multiple approved products, ARTMS is the only solid-target cyclotron technology solution in the U.S. with validated gallium-68 (⁶⁸Ga) and zirconium-89 (⁸⁹Zr) production. For shorter half-life isotopes such as ⁶⁸Ga, QIS^® enables decentralized, high-yield, multi-Curie production. Beyond ⁶⁸Ga and 89Zr, ARTMS continues to advance the high-efficiency, large-scale and cost-effective production of other commercially important radiometals, including technetium-99m (^99mTc) and copper-64 (⁶⁴Cu).

Under the partnership agreement, IBA will offer QIS^® to new and existing cyclotron customers worldwide, so that the accelerator and solid-target capability can be sourced, installed and serviced through a single supplier. QIS^® remains compatible with other cyclotron platforms, and ARTMS continues to serve its existing customers directly. The collaboration aims to accelerate the availability of innovative diagnostic and therapeutic isotopes to support the expansion of theranostics worldwide, through establishing scalable production infrastructures capable of meeting the rapidly growing needs of healthcare providers and patients.

IBA and Telix are working together to advance the future of radiometal-based medicine through a collaboration that brings together leading capabilities across the radiopharmaceutical value chain. By leveraging their respective strengths, IBA and Telix aim to contribute to a more integrated, reliable, and accessible radiopharmaceutical ecosystem.

Loïk-Maël Nys, President of IBA RadioPharma Solutions, commented: “These initiatives reinforce IBA's strategic vision to support the transformation of nuclear medicine toward a broad theranostic landscape relying on radiometals and emerging therapeutic isotopes. By combining IBA's expertise in particle acceleration and radiopharmaceutical manufacturing solutions with the complementary capabilities of ARTMS and Telix, we aim to simplify access to advanced production technologies while accelerating innovation across the radiopharmaceutical value chain.”

Chad Watkins, General Manager Isotope Strategy of Telix Pharmaceuticals, said: "Reliable local supply of gallium-68 and other radiometals is what allows precision oncology to reach more patients. IBA brings the reach and the service capability to put QIS^® within reach of sites that could not easily access it before."

Louvain-la-Neuve, Belgium, 27 August 2026, 7 a.m. - IBA (Ion Beam Applications S.A.), today announces its consolidated results for the first half of 2026, with performance on track with FY 2026 guidance and continued progress towards its profitability improvement trajectory. The period was marked by strong commercial momentum, notably in Proton Therapy and RadioPharma Solutions, as well as the strengthening of IBA’s leadership team and Board to support the Group’s growth and execution of its strategic roadmap.